Justin Klee

After ALS Drug Fails in Phase 3, Amylyx Weighs Pulling the Product From Market

Amylyx Pharmaceuticals co-CEO Justin Klee previously said the company would withdraw ALS drug Relyvrio from the market if it failed its Phase 3 clinical trial. The biotech has set an eight-week timeline to evaluate its next steps.

By Frank Vinluan

Physicians

OmniLife Health’s Clinical Workflow Solution Focuses on Complex Care

OmniLife Health's initial focus with its complex care coordination platform is organ transplant care.

Health Tech

HealthBook+ CEO Shares Vision for How People Can Own Their Health by Leveraging Data and AI

HealthBook+ provides a way for individuals to aggregate and use their personal health information safely and securely to power AI engines that direct people to their next best health action. Importantly, it also gives employers predictive insights to help them provide the most relevant benefits for their employees.